CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Mechanical circulatory support devices for acute right ventricular failure Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? The year in cardiology: heart failure: The year in cardiology 2019 Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection Fraction Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF